Form 4: Enanta Pharmaceuticals Officer Sells Shares for Tax Obligations

Enanta Pharmaceuticals' Executive Director of Accounting, Kathleen S. Capps, sold 323 shares of common stock at a weighted-average price of $14.23 to cover tax withholding obligations related to restricted stock unit settlements.

Summary

• Kathleen S. Capps, Executive Director of Accounting, Controller (Principal Accounting Officer) at Enanta Pharmaceuticals Inc. (ENTA), reported a transaction on December 5, 2025.
• Capps sold 323 shares of Enanta Pharmaceuticals common stock.
• The shares were sold at a weighted-average price of $14.23, with individual transactions ranging from $13.89 to $14.46.
• This sale was a 'sell to cover' transaction, specifically to satisfy tax withholding obligations arising from the settlement of restricted stock unit awards.
• The restricted stock unit awards were granted on November 23, 2022, and November 22, 2023.
• The transaction was not a discretionary sale by the reporting person.
• Following this transaction, Capps beneficially owns 8,377 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event for insiders receiving equity compensation and does not reflect a positive or negative discretionary view on the company's prospects.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This transaction is a routine insider filing related to equity compensation and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in management's outlook on the company.

Key Dates

Keywords

ENANTA PHARMACEUTICALS, ENTA, Form 4, insider transaction, stock sale, restricted stock units, tax withholding, beneficial ownership